期刊
CURRENT OPINION IN NEUROLOGY
卷 27, 期 4, 页码 442-449出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WCO.0000000000000113
关键词
early management; exercise; investigational treatments; Parkinson's disease; treatment options
资金
- Adamas
- Impax
- Medtronic
- St. Jude Medical
- Teva Neuroscience
- UCB
- US World Meds
- Abbvie
- Avid
- Boston Scientific
- Chelsea
- Kyowa
- National Parkinson Foundation
- NIH/NINDS
- Novartis
Purpose of review This review summarizes currently available treatment options and treatment strategies, investigational treatments, and the importance of exercise for early Parkinson's disease. Recent findings The available treatment options for early Parkinson's disease have changed little in the past decade and include carbidopa/levodopa, dopamine agonists, and monoamine oxidase type B (MAO-B) inhibitors. However, we discuss changes in treatment strategies, including dosing and the use of combination therapy used in an attempt to reduce or delay the appearance of motor complications and other adverse events. We will also review several investigational treatments that have shown promise for the treatment of early Parkinson's disease, including a new extended release formulation of carbidopa/levodopa (IPX066), safinamide which inhibits MAO-B, dopamine uptake and glutamate and pardoprunox which is a 5HT-1A agonist and a partial dopamine agonist. Finally, we discuss recent studies focusing on exercise as an important component in the management of early Parkinson's disease. Summary Advances in the management of early Parkinson's disease include evolving treatment strategies, new investigational treatments, and earlier implementation of various forms of exercise.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据